GlassScriptPhysician profile
Ashley Craven
NPI 1154739779
$4,066.95
in general payments reported to CMS, 2019-2025
19 companies · $644 in 2025
The $644 reported for 2025 was more than what 83% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111 · 2020: $255 · 2021: $617 · 2022: $948 · 2023: $824 · 2024: $669 · 2025: $644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,136.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $653.71 | 2022-2025 | Infuse, Miebo, Biotrue One Day |
| Johnson & Johnson Surgical Vision, INC. | $645.52 | 2022-2025 | Lipiflow System Activator (Disposable) |
| Coopervision INC. | $628.72 | 2019-2025 | Myday Contact Lens, Misight Contact Lens |
| Sun Pharmaceutical Industries INC. | $406.19 | 2022-2025 | Cequa, Xelpros |
| Allergan, INC. | $368.45 | 2020-2022 | |
| Kala Pharmaceuticals, INC. | $291.93 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $280.72 | 2020-2023 | |
| Glaukos Corporation | $197.95 | 2025 | Idosetr |
| Johnson & Johnson Vision Care, INC. | $181.30 | 2021-2025 | Acuvue |
| Alcon Vision LLC | $106.23 | 2022-2025 | Rocklatan, Precision 7, Precision7 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $85.65 | 2020 | |
| Lkc Technologies, INC. | $42.05 | 2024 | |
| Tarsus Pharmaceuticals, INC. | $37.68 | 2024-2025 | Xdemvy |
| Mallinckrodt Hospital Products INC. | $36.02 | 2023 | Acthar |
| Abbvie INC. | $26.40 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $23.33 | 2025 | |
| Oyster Point Pharma, INC. | $22.11 | 2025 | Tyrvaya |
| Dompe US, INC. | $17.36 | 2023 | Oxervate |
| Thea Pharma INC. | $15.63 | 2024 | Iyuzeh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Craven listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.